Alerta

MATURATION MEDIUM COMPOSITIONS AND METHODS FOR HUMAN HEART ORGANOID MATURATION

Resumen de: US20260275292A1

A maturation medium and a method for maturing an early embryonic human heart organoid into a mature human heart organoid are provided herein. The maturation medium includes a cell growth medium containing a medium supplement including one or more fatty acid, triiodothyronine (T3) growth hormone, insulin, one or more antioxidant, a sugar, and carnitine; one or more additional fatty acid; an additional carnitine or creatine; and an additional T3 growth hormone. The maturation medium may further include one or more of an additional sugar, an additional antioxidant, and a growth factor. The method includes contacting an early embryonic human heart organoid with one or more maturation medium to produce a mature human heart organoid.

ARTIFICIAL PANCREAS SIMULATOR

Resumen de: WO2026192089A1

The present invention relates to an artificial pancreas simulator and, more particularly, may comprise an infusion pump for administering insulin to a user, a blood glucose meter for measuring the user's blood glucose level at predetermined intervals, a user terminal for communicating with the infusion pump and the blood glucose meter, and an organ simulator for simulating bodily functions of the user related to changes in the user's blood glucose level.

AUTOMATED SCREENING FOR DIABETIC RETINOPATHY SEVERITY USING COLOR FUNDUS IMAGE DATA

Resumen de: US20260279578A1

Methods and systems for evaluating diabetic retinopathy (DR) severity are provided herein. Color fundus imaging data is received for an eye being evaluated for DR. A metric is generated using the color fundus imaging data, the metric indicating a probability that a score for the DR severity in the eye falls within a selected range.

TECHNIQUES FOR DETERMINING AUTOMATED INSULIN DELIVERY DOSAGES

Resumen de: US20260273184A1

Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.

SOLUTION FOR SUSPENDING CELLS, AND USE THEREOF

Resumen de: US20260275287A1

An object of the present invention is to provide a solution for thawing that can maintain or improve the cytotoxic activity of highly active NK cells and the like after thawing. A solution for suspending cells for administration to humans, which satisfies the following criteria: (1) containing potassium ion, (2) having a pH of 4.9 or higher, (3) not containing chloride ions at a concentration of 135 mEq/L or higher, (4) not containing glucose at a concentration of 5.55 mM or higher, (5) not containing calcium ions at a concentration of 0.423 mM or higher, (6) having an osmolarity of 200 to 396 mOsm, and (7) containing any organic acid(s) selected from the group consisting of succinic acid, malic acid, lactic acid, citric acid, and acetic acid.

METHODS AND SYSTEMS TO OPTIMIZE GLUCOSE MONITORING USING VOICE ANALYSIS

Resumen de: US20260272336A1

A method for monitoring a subject’s blood glucose level, comprising: receiving a voiceprint from the subject; correlating the received voiceprint to a determined blood glucose level for the subject, using a predefined correlation model; determining, by comparing the determined blood glucose level to a predetermined acceptable blood glucose level range for the subject, whether the determined blood glucose level is outside the predetermined acceptable blood glucose level range for the subject; and generating an alert when the determined blood glucose level is outside the predetermined acceptable blood glucose level range for the subject.

SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE HEALTH COACH WITH BIOMETRIC DATA INTEGRATION AND PERSONALIZED HEALTH INTERVENTION GENERATION

Resumen de: US20260279592A1

A method uses an artificial intelligence health coach system that includes receiving a voice input from a user, interpreting the voice input with natural language processing performed by an artificial intelligence model, which includes a large language model, and receiving a glucose level from a continuous glucose monitor. The method further includes receiving an insulin level from a database, calculating a Homeostatic Model Assessment of Insulin Resistance score from the glucose level and the insulin level, comparing the score to historical scores associated with the user, and identifying a predicted risk of a hyperglycemic episode. The method also includes generating a preventative health recommendation modified based on whether the score has changed over time, requesting additional health information from the user, modifying the recommendation based on the additional information, and outputting the modified recommendation to the user. The method maintains persistent user data as contextual memory across interactions.

METHODS OF ESTIMATING BLOOD GLUCOSE AND RELATED SYSTEMS

Resumen de: US20260276659A1

A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.

SMART MEDICAL MONITORING WRISTBAND

Resumen de: WO2026192544A1

The invention is a smart medical monitoring wristband developed for use in the healthcare sector. The wristband detects health parameters such as blood pressure, heart rate, oxygen saturation, body temperature, ECG, and blood sugar, and provides real-time remote access to this data. The wristband facilitates easy access to patients for healthcare professionals while enhancing patient comfort by providing music, games, and educational content. Additionally, it increases the number of patients under supervision through an emergency call button and GPS tracking system. Using AI-powered data analysis, it detects abnormal health conditions and automatically notifies the healthcare team. With its lightweight and ergonomic design prioritizing patient comfort, the device can be used securely with encrypted data.

BLOOD GLUCOSE INSIGHT GENERATOR FOR DRIVING APPLICATIONS

Resumen de: US20260272353A1

Systems and methods are described for monitoring blood glucose when driving. The methods may include receiving blood glucose input for a user over a time period, detecting one or more driving events associated with the user over the time period, correlating the blood glucose input with the one or more driving events; determining, based on the correlation, at least one pattern indicating a blood glucose status for the user, generating, based on the blood glucose status and a repository of user data, at least one insight or trend corresponding to the user, and causing presentation of the at least one insight or trend.

NONINVASIVE DEVICE TO ESTIMATE AND TRACK BLOOD GLUCOSE LEVELS

Resumen de: WO2026193386A1

Systems and methods for estimating and tracking blood glucose levels are provided. A method includes receiving, from a sensor, a plurality of photoplethysmography (PPG) signals, deriving an oxygenated hemoglobin concentration signal and a deoxygenated hemoglobin concentration signal from the PPG signals, determining a phase relationship between the oxygenated hemoglobin concentration signal and the deoxygenated hemoglobin concentration signal, generating a glycemic pointer based at least in part on the phase relationship, and generating a first blood glucose level based on the glycemic pointer.

DYNAMIC EQUIVALENT ON BOARD ESTIMATOR

Resumen de: US20260279537A1

Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: US20260272337A1

The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.

Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker

Resumen de: AU2026205448A1

Abstract Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a uPAR-specific chimeric antigen receptor. Also disclosed herein are methods for using the engineered immune cells of the present technology to treat or ameliorate the effects of cancer and senescence-associated pathologies (e.g., lung fibrosis, atherosclerosis, Alzheimer's disease, diabetes, liver fibrosis, chronic kidney disease, aging, or osteoarthritis) by selectively targeting senescent cells. Also provided herein are methods for detecting the senescent cell burden in a patient. Abstract

IMPROVED CELL IMPLANTS AND METHODS OF USING THE SAME

Resumen de: WO2026193167A1

The present disclosure provides modified cells for use in cell therapies to treat diabetes, as well as methods for preparing such cells. More specifically, the present disclosure provides genetically modified cells that reduce the production of extracellular matrix following implantation and/or express a novel peptide that targets the cells for destruction without impacting the subject's native cells.

CUSTOMIZED WEARABLE SALIVA BIOSENSOR FOR REAL-TIME CONTINUOUS HEALTH MONITORING

Resumen de: US20260272335A1

A customized wearable saliva biosensor system for continuous, real-time, in-situ monitoring of biochemical markers in human saliva. The system integrates a multi-gate organic electrochemical transistor biosensor employing an organic semiconductor channel with enzyme-functionalized gate electrodes, a compact wireless integrated circuit with Bluetooth data transmission, a power subsystem optionally incorporating piezoelectric and/or triboelectric nanogenerators, and a custom-fitted wearable substrate fabricated from a three-dimensional scan of the user's dental anatomy. The system is positioned within the oral cavity in proximity to the sublingual glands for direct detection of fresh saliva at the point of secretion. A differential measurement architecture comparing an enzyme gate to a control gate provides selective, real-time detection of target biomarkers including glucose, lactate, and uric acid. Measured data is wirelessly transmitted to a companion mobile application for display to the user.

METHODS, SYSTEMS, AND DEVICES FOR IMPROVED SENSORS FOR CONTINUOUS GLUCOSE MONITORING

Resumen de: EP4806353A2

Methods, systems, and devices for continuous glucose monitoring. More particularly, the methods, systems, and devices describe a working electrode with a GOx sensor and a background electrode in which the background electrode has no GOx sensor. The system may then compare the first signal and the second signal to detect ingestion of a medication by the user. The system may generate a sensor glucose value based on the comparison.

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Resumen de: EP4806354A2

0001 The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.

CELL CULTURE

Resumen de: EP4806508A2

A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.

NANOPOROUS STRUCTURE AND NON-ENZYMATIC GLUCOSE-SENSING DEVICE AND SYSTEM

Resumen de: EP4807357A2

A method of making a nanoporous layer comprises providing a liquid composition comprising a surfactant and metal ions, adding a reducing agent to cause reduction of at least part of the metal ions to form nanoparticles, removing the surfactant to form a second colloid, adjusting a concentration of the nanoparticles to provide a colloid composition, dispensing the colloid composition over a substrate, and subjecting the dispensed colloid composition to drying to form the nanoporous layer.

IMMUNOSUPPRESSANT RELEASING COATINGS

Resumen de: EP4806351A2

0001 Embodiments of the invention provide compositions useful in implantable devices such as analyte sensors as well as methods for making and using such compositions and devices. In typical embodiments of the invention, the device is a glucose sensor comprising a polymeric composition disposed on a flexible assembly within the sensor that includes amounts of one or more immunosuppressant agents designed to provide such sensors with improved material properties such as enhanced biocompatibility.

RECOMBINANT PROTEIN COMPOSITIONS USEFUL FOR WOUND HEALING

Resumen de: US20260263559A1

0000 Described herein are compositions comprising a combination of active agents, such as recombinant fibroblast growth factor-7 (FGF-7), recombinant follistatin, recombinant interleukin-6 (IL-6), recombinant transforming growth factor beta-1 (TGFβ-1), recombinant urokinase receptor (uPAR), and a carrier, which compositions may further comprise recombinant angiopoietin-1 (ANG-1), recombinant hepatocyte growth factor (HGF), recombinant insulin, and/or recombinant vascular endothelial growth factor (VEGF). Also provided herein are methods of treating wounds, accelerating healing of a wound, accelerating angiogenesis, and/or reducing scarring, as well as methods for culturing cells in vitro, and for cell delivery in vivo, using compositions of the present invention.

METHOD AND APPARATUS FOR REAL-TIME CALCULATION OF GASTRIC EMPTYING RATE OF PATIENT

Resumen de: WO2026184101A1

A method and apparatus for real-time calculation of a gastric emptying rate of a patient. The method comprises: S1, using a fluorescence indicator method to determine a gastric emptying trend line representing a gastric emptying rate of a patient; S2, monitoring blood glucose of the patient in real time; and S3, correcting the gastric emptying rate of the patient in a personalized manner on the basis of a real-time blood glucose monitoring value of the patient. The apparatus comprises: a fluorescence measurement unit, configured to perform fluorescence measurement on a patient by using a fluorescence indicator method, to determine a gastric emptying trend line representing a gastric emptying rate of the patient; a blood glucose measurement unit, configured to monitor blood glucose of the patient in real time; and a calculation unit, configured to correct the gastric emptying rate of the patient in a personalized manner on the basis of a real-time blood glucose monitoring value of the patient, wherein the corrected gastric emptying rate can be calculated using a specific formula, and the specific formula incorporates a blood glucose rate-of-change coefficient for quantifying the impact of blood glucose changes on the gastric emptying rate, as well as the rate of change of blood glucose.

SYSTEM AND METHOD FOR AUTOMATED INSULIN DELIVERY USING ARTIFICIAL NEURAL NETWORK

Resumen de: AU2025232283A1

An automated insulin delivery system provides an insulin injection that is computed by adding (i) the recommendation of an artificial neural network trained to mimic a constrained model predictive controller dosing rule from a neural network implementing an artificial pancreas (ii) a hypoglycemia mitigation system includeds a correction (one dose computed as the correction down to 110mg/dl based on prevailing continuous glucose monitoring and once an hour at most, unless there is a triggering BPS and G>180 mg/dl), and (iii) the current basal rate (output of the Performance Assessment System, (PAS)); that amount is then saturated by the Safety Supervision System, SSM. Finally, a priming bolus from the Bolus Priming System, BPS, is added to the total if the conditions for large glycemic excursions are detected, also saturated by SSM.

METHOD FOR ONLINE MONITORING OF VITAL SIGN PARAMETERS OF HOST AND MULTI-WORKING-ELECTRODE SYSTEM

Nº publicación: WO2026184355A1 10/09/2026

Solicitante:

JIANGSU YUWELL POCTECH BIOTECHNOLOGY CO LTD [CN]
JIANGSU YUEKAI BIOTECHNOLOGY CO LTD [CN]
ZHEJIANG POCTECH CO LTD [CN]
\u6C5F\u82CF\u9C7C\u8DC3\u51EF\u7ACB\u7279\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
\u6C5F\u82CF\u8DC3\u51EF\u751F\u7269\u6280\u672F\u6709\u9650\u516C\u53F8
\u6D59\u6C5F\u51EF\u7ACB\u7279\u533B\u7597\u5668\u68B0\u6709\u9650\u516C\u53F8

Resumen de: WO2026184355A1

The present application relates to a method for online monitoring of vital sign parameters of a host and a multi-working-electrode system, which can improve the accuracy of glucose monitoring. The method comprises: using a first working electrode to acquire a first vital sign parameter of a host; using a second working electrode to acquire a second vital sign parameter of the host; and acquiring, on the basis of the first vital sign parameter and the second vital sign parameter, a target glucose concentration of the host. The first working electrode and the second working electrode are arranged on the same substrate, and can acquire the first vital sign parameter and the second vital sign parameter, respectively, at different depths of the host's tissue independently of each other. The two working electrodes can effectively determine analyte concentrations at different depths, which, combined with the vital sign parameters generated by the different working electrodes, can comprehensively provide more reliable continuous monitoring results, thereby improving the accuracy of monitoring.